Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PMT-307 (also known as HO-4450) is a bifunctional small molecule designed as a Paramagnetic Amyloid Ligand (PAL) for the potential treatment of Alzheimer's disease. It features a stilbene scaffold coupled with a six-membered nitroxyl ring. The molecule operates through a dual mechanism: it binds to and remodels the secondary structure of toxic amyloid-beta oligomers (AβOs), specifically reducing the fraction of antiparallel β-strands, and acts as a catalytic antioxidant by mimicking the activity of superoxide dismutase (SOD). This dual action aims to neutralize both the structural toxicity of amyloid aggregates and the associated oxidative stress in the brain. Preclinical studies in Alzheimer's disease mouse models have indicated modest therapeutic effects and protection against Aβ-induced cytotoxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PMT-307.